



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

35812

PATENT TRADEMARK OFFICE

Art Unit : 1616

Examiner :

Serial No. : 10/722,737

Filed : November 25, 2003

Docket: BSG 021 US

Inventors : Bradley S. Galer

: Arnold R. Gammaitoni

: Robert D. Dworkin

Title : COMPOSITION AND METHOD

Confirmation No.: 7300

: FOR TREATING NEUROPATHIC

: SENSORY LOSS

Dated: April 28, 2004

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

We submit herewith the usual Form PTO-1449 together with copies of publications listed therein. They are submitted to comply with the Applicants' duty of disclosure under 37 C.F.R. §1.56 and are believed related to this application.

We are submitting this in the spirit of voluntary disclosure and look forward with interest to the Examiner's action at an early date on the merits of the case.

It is accordingly requested that the Information Disclosure Statement be officially entered in the file of this case and that appropriate notification be made that it was considered in the prosecution of the case.

Respectfully submitted,


Guy T. Donatiello

Reg. No. 33,167

Attorney for Applicants

GTD:gj

(610) 558-9800



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/722,737
Filing Date	November 25, 2003
First Named Inventor	Bradley S. Galer et al
Art Unit	1616
Examiner Name	
Attorney Docket Number	BSG 021 US

Sheet

of

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 2003/0124174 A1	07-03-2003	Galer	
		US- 2002/0049229 A1	04-25-2002	Yamamoto et al	
		US- 2002/0040025 A1	04-04-2002	Hogenkamp et al.	
		US- 2002/0037926 A1	03-28-2002	Lan	
		US- 6,355,637 B1	03-12-2002	Axt et al.	
		US- 6,337,423 B1	01-08-2002	Axt et al.	
		US- 6,248,788 B1	06-19-2001	Robbins et al.	
		US- 6,166,085	12-26-2000	Chaplan et al.	
		US- 6,147,102	11-14-2000	Borgman	
		US- 5,985,933	11-16-1999	Zeitlin	
		US- 5,976,547	11-02-1999	Archer et al.	
		US- 5,885,597	03-23-1999	Botknecht et al.	
		US- 5,866,157	02-02-1999	Higo et al.	
		US- 5,849,737	12-15-1998	Chaplan et al	
		US- 5,776,952	07-07-1998	Liedtke	
		US- 5,741,510	04-21-1998	Rolf et al.	
		US- 5,709,869	01-20-1998	Hind	
		US- 5,668,830	11-18-1997	Berger et al	
		US- 5,411,738	05-02-1995	Hind	

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	10/722,737
Filing Date	November 25, 2003
First Named Inventor	Bradley S. Galer et al.
Art Unit	1616
Examiner Name	
Attorney Docket Number	BSG 021 US

[illegible][illegible]Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to office. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

35812

PATENT TRADEMARK OFFICE

Art Unit : 1616

Examiner :

Serial No. : 10/722,737

Filed : November 25, 2003

Docket: BSG 021 US

Inventors : Bradley S. Galer

: Arnold R. Gammaitoni

: Robert D. Dworkin

Title : COMPOSITION AND METHOD

Confirmation No.: 7300

: FOR TREATING NEUROPATHIC

: SENSORY LOSS

Dated: April 28, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Certificate of Mailing Under 37 CFR 1.8

For

Postcard

Information Disclosure Statement
Form PTO-1449 w/copies of publications

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

Endo Pharmaceuticals Inc.
Customer No. 35812

By: 

Date: 28 April 2004